Researchers at the La Jolla Institute for Immunology and Columbia University have found evidence that amyotrophic lateral sclerosis (ALS) may be an autoimmune disease, with CD4+ T cells mistakenly targeting proteins in the nervous system. The study highlights two patient groups with differing survival times based on their immune responses, suggesting that enhancing protective immune responses could lead to new ALS treatments.